検索
Genmab A/S
GMABウォッチリストに追加
28.870USD
+0.230+0.80%
終値 07-31 16:00（ET）15分遅れの株価
17.79B時価総額
21.75直近12ヶ月PER
詳細情報 Genmab A/S 企業名
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/Sの企業情報
企業コードGMAB
会社名Genmab A/S
上場日Oct 01, 2000
最高経営責任者「CEO」Van De Winkel (Jan G.J)
従業員数2682
証券種類Depository Receipt
決算期末Oct 01
本社所在地Carl Jacobsens Vej 30
都市VALBY
証券取引所NASDAQ OMX - NASDAQ BASIC
国Denmark
郵便番号2500
電話番号4570202728
ウェブサイトhttps://www.genmab.com/
企業コードGMAB
上場日Oct 01, 2000
最高経営責任者「CEO」Van De Winkel (Jan G.J)
Genmab A/Sの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
よくある質問
Genmab A/Sの上位5名の株主は誰ですか？
Genmab A/Sの上位5名の株主は以下のとおりです。Dr. Jan G.J. Van De Winkel, Ph.D.
Genmab A/S（GMAB）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Genmab A/Sの株式を保有している機関は564社あり、保有株式の総市場価値は約74.31Mで、全体の12.10%を占めています。2025Q4と比較して、機関の持ち株は-2989185.00増加しています。
Genmab A/Sの最大の収益源は何ですか？
2026Q1において、Royalties部門がGenmab A/Sにとって最大の収益を生み出しており、その金額は3.10Bで、全収益の83.39%を占めています。